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ABSTRACT
Wecurrently calculate area under the busulfan concentration time curve (AUC) using 7 plasma busulfan concen-
trations (AUC7) drawn after the first of 16 i.v. busulfan doses given as a 2-hour infusion every 6 hours. The aim of
this study was to develop and validate limited sampling strategies (LSSs) using 3 or fewer busulfan concentration
values with which to reliably calculate AUC in children undergoing hematopoietic stem cell transplant (HSCT).
Children in the development group (44) received i.v. busulfan at Sick Kids; the validation group consisted of 35
children who received care at CHU Ste-Justine. Busulfan doses given and subsequent plasma busulfan concen-
trations were recorded. LSSs using 1 to 3 concentration-time points were developed using multiple linear
regression. LSS were considered to be acceptable when adjusted r2 . 0.9, mean bias \15% and precision
\15%. Extent of agreement between the AUC7 values and the LSS AUC was assessed by the intraclass corre-
lation coefficient (ICC) and Bland-Altman (BA) analysis. Agreement was considered to be excellent when the
lower limit of the 95% confidence limit of the ICC exceeded 0.9 andwhen the limits of agreement in the BA anal-
ysis were ±15% for both AUC and dose. Administration of the theoretic adjusted busulfan doses based on each
LSS was simulated and cases where the resulting AUCwas.1500 or\900 mM$min were noted. LSSs using 1, 2,
or 3 plasma busulfan concentrations were developed that showed excellent agreement with AUC7 and adjusted
busulfan doses. In the validation sample, only the 2- and 3-point LSSs demonstrated acceptable precision and
lack of bias. LSSs using 2 or 3 plasma busulfan concentrations can be used to reliably estimate busulfan AUC after
IV administration in children undergoing HSCT.
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A relationship between busulfan dose intensity, ex-
pressed either as the area under the plasma busulfan
concentration versus time curve (AUC) or the average
plasma concentration, and certain hematopoietic stem
cell transplant (HSCT) outcomes has been described
[1-3]. This relationship is best substantiated in adults
with chronic myelogenous leukemia receiving oral bu-
sulfan [4]. The strength of this relationship in other
populations and circumstances such as children under-
going HSCT is less clear. Nevertheless, in many576HSCT centers the standard of care in patients receiv-
ing busulfan-containing preparative regimens includes
the determination of plasma busulfan concentrations
and calculation of pharmacokinetic parameters after
the first of 16 i.v. busulfan doses given every 6 hours.
Subsequent i.v. busulfan doses are adjusted to achieve
target parameters with a view to minimizing adverse
HSCT outcomes such as hepatic venous occlusive dis-
ease and engraftment failure.
Traditionally, we have calculated busulfan AUC
using 7 plasma concentrations (AUC7) in the 4 hours
Limited Sampling Strategies for IV Busulfan AUC 577following the 2-hour busulfan dose infusion and prior
to the second busulfan dose. We hypothesized that
a sampling schedule using fewer samples could result
in an AUC value similar to that calculated using 7 sam-
ples, and would lead to a dose adjustment clinically
similar to that made based on the AUC7 value. Use
of fewer samples to calculate busulfan AUC would re-
sult in cost savings (nursing workload, assay costs), re-
duce patient inconvenience related to obtaining blood
samples, and reduce the volume of blood required
from each patient.
The objective of this study was to develop and
validate limited sampling strategies (LSSs) using 3 or
fewer busulfan concentration values with which to re-
liably calculate busulfan AUC in children undergoing
HSCT. The extent of agreement between the AUC7
and the AUC calculated using each LSS was evaluated.
PATIENTS AND METHODS
This study was approved by each of our institu-
tions’ research ethics boards.
Development Phase
Patients who received i.v. busulfan (Busulfex,
PDLBioPharma, RedwoodCity, CA) for conditioning
prior to HSCT from April 1, 2003 through January,
2006 at The Hospital for Sick Children, Toronto,
Canada, were identified from pharmacy records. The
health records of these patients were reviewed to obtain
information including: demographic information, bu-
sulfan doses received, busulfan dose administration
times, and plasma busulfan concentrations.
Busulfan AUC calculation. Busulfan was given as
an i.v. infusion over 2 hours via 1 lumen of a double-lu-
men central venous catheter. Blood samples were
drawn for plasma busulfan determination 2 (at the
end of the infusion), 2.25, 2.5, 3, 4, 5, and 6 hours
from the start of the infusion. Samples were taken
from the catheter lumen that was not used for dose ad-
ministration. Plasma busulfan concentrations were as-
sayed by gas chromatography with electron capture
detection by a laboratory that participates in the profi-
ciency testing program organized by PDL BioPharma
[5,6]. The coefficient of variation of the assay is 3.8%
to 6.0%. Busulfan AUC was calculated using 1-com-
partmental analysis using all 7 of the available data
points (AUC7; WinNonLin version 5.0.1). A plasma
busulfan concentration of 0 immediately before dose
administration was assumed.
Limited sampling strategy development. The
relationship between AUC7 plasma busulfan concen-
trations at individual time points after i.v. administra-
tion was assessed by the Spearman rho correlation
coefficient. LSSs using 1 to 3 concentration-time
points were developed via multiple linear regression
analysis. The association between the AUC7 and theAUC values predicted by eachLSSwas described using
the adjusted coefficient of determination (r2); values
.0.9 were considered acceptable. Bias and precision
of the LSSs were measured using the mean prediction
error (bias) and the root-mean-squared prediction er-
ror (precision), respectively. Bias and precision values
of\15% were considered to be acceptable.
Busulfan dose adjustment. Based on a target
AUC of 1300 mM$min, a theoretic adjusted busulfan
dose was calculated for each patient using all LSSs
that met the criteria for acceptability. The AUC that
would have been achieved after simulated administra-
tion of the theoretic adjusted busulfan dose was then
calculated using the AUC7 value. Patients who
achieved an AUC\900 mM$min or .1500 mM$min
under simulation were noted.
Extent of agreement. Intraclass correlation coef-
ficient (ICC; parallel, 1-way random effect model;
SPSS version 13.0.1 for Windows) and Bland-Altman
(BA) analysis were used to assess the extent of agree-
ment between AUC7 and the AUC values generated
by each LSS. The presence of equal variance within
the AUC7 and predicted AUC values was evaluated
by determining the Spearman rho correlation coeffi-
cient between the residuals (AUC72 AUC predicted)
and the predicted values and by plotting the residuals
against the predicted AUC values. Variance was
deemed to be equal if no significant linear relationship
existed between the residuals and the predicted AUC
values and if plots of the residuals against the predicted
values demonstrated random scatter about the zero
reference line. If variance was deemed to be unequal,
the data were log transformed and the variance was
reevaluated. Agreement was considered to be excellent
when the lower limit of the 95% confidence limit of
the ICC exceeded 0.9.
In the BAanalysis, the difference (bias) between the
AUC calculated using a LSS and the AUC7 (% differ-
ence 5 100 ([AUC7 – AUC-LSS]/mean of AUC7 and
AUC-LSS) was plotted against the mean of the 2
values. The limits of agreement (mean % difference
62 SD) were calculated. Clinically acceptable limits
of agreement for AUC were set as 6200 mM$min
(15%) and were based on a target AUC of 1300
mM$min and a target AUC range of 900 to 1500
mM$min.
Validation Phase
Patients who received i.v. busulfan (Busulfex,
PDL BioPharma) for conditioning prior to HSCT
from 2001 through 2006 at CHU Sainte-Justine,
Montreal, Canada, were identified from HSCT re-
cords. The health records of these patients were
reviewed to obtain information as described in the
development phase.
Busulfan AUC calculation. Busulfan was given as
an i.v. infusion over 2 hours. Seven to 8 blood samples
578 L. L. Dupuis et al.were drawn for plasma busulfan determination at ap-
proximately 2 (at the end of the infusion), 2.25, 2.5,
3, 4, 5, and 6 hours from the start of the infusion.
Plasma busulfan concentrations were assayed by
HPLC-UV by a laboratory that participates in the
proficiency testing program organized by PDL Bio-
Pharma [7]. The coefficient of variation of the assay
is 7% to 12%. Busulfan AUC was calculated as de-
scribed above.
LSS validation. The association between the AUC
values calculated using all available data points and the
AUC values predicted by each LSS that met the crite-
ria for acceptability, which had been set in the develop-
ment phase (ie, r2 . 0.9; bias and precision\15%;
limits of agreement for AUC 6 200 mM$min) was de-
termined as described in the development phase.
Again, based on a target AUC of 1300 mM$min, a the-
oretic adjusted busulfan dose was calculated using the
AUC values calculated using each LSS that met the
criteria for acceptability. The extent of agreement be-
tween the AUC7 values and those calculated by each
acceptable LSS was determined using the methodol-
ogy described in the development phase. The AUC
that would have been achieved after simulated admin-
istration of the theoretic adjusted busulfan dose calcu-
lated using the AUC determined by each LSS was
calculated using the AUC7 value. Patients who
achieved an AUC\900 mM$min or .1500 mM$min
under simulation were noted.
RESULTS
Development Phase
Forty-four children, 0.3 to 16 years of age, received
i.v. busulfan at The Hospital for Sick Children during
the study period and were included in this analysis.
Demographic data and information regarding the bu-
sulfan dose administered are presented in Table 1.
LSS development. Plasma busulfan concentra-
tions drawn at every time point after the 2-hour infu-
sion correlated strongly with AUC7 (Table 2;
Spearman rho coefficient 5 0.709-0.985). Details re-
garding the LSSs that met the criteria for acceptability
(ie, adjusted r2 . 0.9, mean bias\15% and precision
\15%) are presented in Table 3. Mean AUC7 values
and AUC values generated by each LSS are presented
in Table 4.
Busulfan dose adjustment. When administration
of the doses calculated using any of the 3 LSSs was sim-
ulated and the resulting AUC was calculated using the
AUC7 value, all patients included in the development
phase achieved an AUC within the target range (900-
1500 mM$min).
Extent of agreement. Variance within the AUC7
and predicted AUC values was found to be equal (data
not shown); log transformation of the data was not
Table 1. Demographic Data and Information Regarding the i.v. Busulfan Dose Administered to the Development and Validation Patient Groups
Development Group Validation Group
Number of patients 44 35
Mean age ± SD in years (median; range) 5.0 ± 5.21 (3.0; 0.3 to 16.2) 8.5 ± 6.14 (8.1; 0.4 to 18.3)
Underlying diagnosis (number of patients; %)
Acute myelogenous leukemia 10 (23) 12 (34)
Acute lymphoblastic leukemia 0 5 (14)
Immune deficiency syndrome 8 (18) 1 (3)
Histiocytosis 4 (9) 0
Chronic myelogenous leukemia 4 (9) 1 (3)
Hurler syndrome 4 (9) 3 (9)
Sickle cell anemia 0 4 (11)
Myelodysplastic syndrome 0 5 (14)
Beta-thalassemia 3 (7) 1 (3)
Medulloblastoma 2 (5) 0
Osteopetrosis 2 (5) 0
Wiskott-Aldrich syndrome 2 (5) 0
Other 5 (11) 3 (9)
Number of patients given phenytoin 44 7
Mean initial busulfan dose in mg/kg* (median; range) 1.02 ± 0.178 (1.01; 0.56 to 1.45) 0.82 ± 0.100 (0.80; 0.63 to 1.09)
SD indicates standard deviation.
*Actual body weight.
Table 2. Development Phase: Spearman Rho Correlation Coefficients for
AUC7 and Plasma Busulfan Concentrations at Time Points after the Start
of a 2-Hour Infusion in 44 Patients
Sampling Time
(Hours after Start
of 2-Hour Infusion)
Spearman Rho
Coefficient
Significance
(2-Tailed)
2 0.709 \0.01
2.25 0.767 \0.01
2.5 0.855 \0.01
3 0.925 \0.01
4 0.982 \0.01
5 0.985 \0.01
6 0.952 \0.01
AUC7 indicates area under the busulfan concentration versus time
curve calculated using 7 data points.
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Sample Times (Hours from
Start of 2 Hour Infusion) Limited Sampling Strategy Equation Adjusted r2 Mean Bias (%; 95% CI) Precision (%)
5 596.3 (C5) 1 123.3 0.966 0.17 (21.3 to 1.0) 3.9
4 and 5 240.4 (C4) 1 328.8 (C5) 1 19.2 0.985 20.05 (20.8 to 0.7) 2.5
4, 5, and 6 229.0 (C4) 1 220.9 (C5) 1 136.2 (C6) 1 61.2 0.990 20.03 (20.7 to 0.6) 2.3
CI indicates confidence interval; C4, C5, C6, busulfan plasma concentration 4, 5, and 6 hours after the start of a 2-hour infusion, respectively.necessary. Excellent agreement (ICC 0.983-0.995;
Table 5) was observed between AUC7 and the AUC
values generated using the LSSs using 1, 2, and 3
plasma busulfan concentrations. The precision of
these LSSs was \5% and mean bias was very small
(20.03%-0.17%). The BA plots for those LSSs that
met the clinically acceptable limits of agreement set
a priori (AUC 615%) are presented in Figure 1.
Validation Phase
Thirty-five children, aged 0.4 to 18.3 years of age,
who received i.v. busulfan at CHU Ste-Justine during
the study period were included in this analysis. Demo-
graphic data and information regarding the busulfan
dose administered are presented in Table 1.
LSS validation. Mean AUC values calculated us-
ing all available data points and via all acceptable
LSSs identified in the validation phase are presented
in Table 4. Variance within the AUC7 and predicted
AUC values was found to be equal (data not shown);
log transformation of the data was not necessary. Ex-
cellent agreement was again observed between
AUC7 and the AUC values predicted by the LSS strat-
egies (ICC 0.957 to 0.970; Table 5) though the limits
of agreement of the 1-sample LSS exceeded 15%.
Again, the limits of agreement of the 1-sample LSS
were 211.9% to 15.8%, and thus exceeded the limit
of615% that had been set a priori. The BA plots com-
paring actual AUC7 and the AUC values predicted by
the LSSs are presented in Figure 2.
The difference between the AUC7 and the AUC
calculated using the 2- and 3-sample LSSs exceeded
the limits of agreement of615% set a priori in a singlepatient. The difference between the AUC7 and the
2-point and 3-point AUCLSSs was 27% and 22%, re-
spectively. This patient was an 8-year-old with myelo-
dysplastic syndrome who weighed 94% of ideal body
weight, received lorazepam for prophylaxis for busul-
fan-induced seizures, and exhibited a very short busul-
fan half-life (78 minutes). The difference between the
AUC7 and the 2-sample and 3-sample AUCLSSs
was 18% and 15%, respectively, in another patient.
This patient was a 13.5-year-old with acute lympho-
blastic leukemia who weighed 100% of ideal body
weight, received midazolam for prophylaxis of busul-
fan-induced seizures and exhibited a very long busul-
fan half-life (258 minutes). No other distinguishing
features of these patients were evident.
No patient achieved an AUC\900 mM$min when
administration of the theoretic adjusted busulfan doses
was simulated. Two patients achieved AUC values
.1500 mM$min under each LSS (2-sample LSS:
1706 and 1550; 3-sample LSS: 1626 and 1511
mM$min, respectively). Both of these patients are de-
scribed in the previous paragraph.
DISCUSSION
Wehave developed and externally validated 2 LSSs
using either 2 or 3 busulfan concentration-time points
for calculating AUC in children receiving i.v. busulfan
prior to HSCT. These LSSs predict AUC7 with good
precision and little bias. The AUC values predicted by
these LSSs and the adjusted busulfan doses derived us-
ing the LSSs have excellent agreement, both statisti-
cally and clinically, with those calculated using 7 data
points.Table 4.Mean Actual and Predicted AUC and Ideal Busulfan Dose Values (95% Confidence Interval) Generated during Development and Validation Phases
Development Phase Validation Phase
Mean AUC7 1268.6 (1182.2-1354.9) 880.2 (791.4-969.0)
Mean AUC: 1-point LSS 1268.6 (1183.6-1353.5) 892.4 (814.4-970.3)
Mean AUC: 2-point LSS 1268.6 (1182.8-1354.3) 850.2 (772.4-928.0)
Mean AUC: 3-point LSS 1268.6 (1182.6-1354.5) 857.9* (773.0-942.9)
Mean ideal busulfan dose (mg) based on:
AUC7 21.2 (16.7-25.7) 37.6 (30.3-44.9)
1-point LSS 21.1 (16.6-25.6) 36.9 (29.8-44.0)
2-point LSS 21.3 (16.7-25.9) 38.8 (31.3-46.3)
3-point LSS 21.2 (16.7-25.7) 39.9 (32.5-47.3)
AUC indicates area under the plasma busulfan versus time curve; AUC7, AUC calculated using 7 data points; LSS, limited sampling strategy.
*Based on sample size of 32; 3 patients did not have plasma busulfan concentrations drawn at hour 6.
580 L. L. Dupuis et al.Table 5. Extent of Agreement between AUC Values Predicted by the Limited Sampling Strategies and AUC7
Development Phase Validation Phase
Limited Sampling
Strategy Equation ICC (95% CI) Limits of Agreement* (%) ICC (95% CI) Limits of Agreement* (%)
596.3(C5) 1 123.3 0.983 (0.970-0.991) 28.0 to 7.7 0.957 (0.917-0.978) 211.9 to 15.8
240.4(C4) 1 328.8(C5) 1 19.2 0.993 (0.987-0.996) 25.1 to 5.0 0.961 (0.924-0.980) 214.3 to 7.9
229.0(C4) 1 220.9(C5) 1 136.2(C6) 1
61.2
0.995 (0.992-0.997) 24.6 to 4.5 0.970† (0.941-0.985) 212.4 to 9.8†
ICC indicates parallel, 1-way random effect model intraclass correlation coefficient; CI, confidence interval; C4, C5, C6, busulfan concentration
4, 5, and 6 hours after the start of a 2-hour infusion, respectively.
*As per Bland-Altman (BA) analysis.
†Based on sample size of 32; 3 patients did not have plasma busulfan concentrations drawn at hour 6.Traditionally, the full assessment of AUC of a drug
that displays 1-compartmental disposition such as bu-
sulfan, requires a minimum of 7 concentration-time
points after the first dose. Evaluation of the AUC after
the first dose allows us to assume that the initial con-
centration at time zero is 0; this constitutes the eighth
data point. Assessment of AUC is therefore very labor
intensive because nurses must obtain many samples
that then must be analyzed. Delays in receiving results
may delay administration of subsequent individualized
6 hourly busulfan doses. In our institutions, plasma
busulfan concentrations are usually available 6 hoursafter the last sample is drawn and patients usually
receive an adjusted dose by the fourth busulfan dose.
Other investigators have developed LSSs after i.v.
busulfan administration to adults. Vaughan et al. [8]
developed a LSS in 59 adults each of whom had 4 to
12 plasma busulfan concentrations determined after
the first i.v. busulfan dose. Their approach was
validated in 96 patients. AUC calculation using 4 or
5 samples was recommended because this number of
samples accommodates the occasional pragmatic
need to discard samples that have yielded questionable
results. This analysis emphasized the number of data500 1000 1500 2000 2500
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Figure 1.Development phase: BA plots of AUC7 versus AUCpredicted by each limited sampling strategy (LSS). (A) 1-sample LSS; (B) 2-sample
LSS; (C) 3-sample LSS.
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Figure 2.Validation phase: BA plots of AUC7 versus AUC predicted by each limited sampling strategy (LSS). (A) 1-point LSS; (B) 2-point LSS;
(C) 3-point LSS.points required for AUC determination, not the ideal
timing of sampling required for efficient and reliable
determination of AUC. In addition, the performance
of the LSS was evaluated using tests of differences be-
tween mean AUC, elimination half-life, and coeffi-
cient of variations rather than by an evaluation of the
agreement between individual AUC or dose adjust-
ment pairs. Precision and bias of the LSS were not
specified. As noted by others, assessment of agreement
using the correlation coefficient or comparisons of
mean values is flawed [9].
Nguyen et al. [10] also developed a LSS in adults
receiving i.v. busulfan using Bayesian methods: data
from 103 and 24 patients were used to develop and val-
idate the model, respectively. A 2-sample LSS using
plasma busulfan concentrations obtained at 2.25 and
6 hours from the start of a 2-hour infusion predicted
the AUC with no signficiant bias and good precision.
The correlation coefficient was used to compare the
predicted AUC based on the LSS and the AUC based
on the complete data set. Application of this LSS
requires use of Bayesian methodology.
Neither of the LSSs proposed to date are ideal.
The first8 suffers from lack of demonstrated agreement
with the results of the full data set, whereas the sec-
ond10 requires the use of methodology that is not read-
ily accessible to many clinicians. The LSSs we proposewill reliably and accurately predict AUC in children
receiving i.v. busulfan over 2 hours without the use
of sophisticated computer modeling. Use of the LSSs
described here is limited to the population used in their
development and validation: children receiving the
first of 16 2 hour busulfan infusions. As well, adherence
to the timing of blood sampling must be rigorous. De-
termination of AUC using the traditional 7-point
method should be considered for patients who exhibit
extreme busulfan half-lives (very short or very long)
because the LSS described here may not predict actual
AUC accurately in such patients.
We recommend adoption of the 3-sample LSS so
as to minimize complications should 1 of the samples
yield questionable results and need to be discarded.
Depending on which sample is forfeit, it may be possi-
ble to calculate AUC bymeans of the 2-sample LSS. In
our institution, the adoption of the 3-sample LSS will
not only reduce assay costs, nursing and laboratory
technician workload, and patient inconvenience, but
will also improve result turnover and permit dose ad-
justment by the third busulfan dose.
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